PMID- 19758141
OWN - NLM
STAT- MEDLINE
DCOM- 20091029
LR  - 20090917
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
VI  - 1173
DP  - 2009 Sep
TI  - Antibodies to neurofilaments.
PG  - 130-6
LID - 10.1111/j.1749-6632.2009.04624.x [doi]
AB  - Immune responses to neuronal proteins are a frequent occurrence in 
      neurodegenerative diseases. This study determines the occurrence of 
      autoantibodies to the three neurofilament subunits in phosphorylated and 
      dephosphorylated forms and relates these measures to age, human leukocyte antigen 
      (HLA), and severity of disease in Down syndrome (DS). IgG-type antibodies to 
      three neurofilament (NF) subunits, NF-L, NF-M, and NF-H, in both phosphorylated 
      and dephosphorylated forms were tested by immunoblot in 128 patients with DS and 
      compared to antibody levels in 94 normal controls. DS was revealed by karyotype 
      analysis. Antibodies to dephospho-NF-M, NF-M, and NF-L were more common in DS 
      samples than in controls. Total pools of DS and control samples had similar 
      frequency of antibodies to NF-H, but there was a higher prevalence of antibodies 
      against NF-H in DS patients with moderate or mild disability (43.0%) compared 
      with those having serious disability (14.3%). No NF-H antibody was seen among 
      young children (age 14 years or younger) of the latter group. The HLA-DR15 allele 
      was negatively correlated with antibodies against NF-H. The high prevalence of 
      antibodies to neurofilament proteins and the differences between DS and control 
      samples may reflect the cross-talk between neural and immune systems that could 
      have an important role in defending neural structures from neurodegenerative 
      processes. In children with DS the presence of antibodies to NF-H might reflect a 
      more favorable prognosis.
FAU - Talja, Ija
AU  - Talja I
AD  - Immunology Group, Institute of General and Molecular Pathology, University of 
      Tartu, Tartu, Estonia.
FAU - Reimand, Tiia
AU  - Reimand T
FAU - Uibo, Oivi
AU  - Uibo O
FAU - Reimand, Koit
AU  - Reimand K
FAU - Aun, Silver
AU  - Aun S
FAU - Talvik, Tiina
AU  - Talvik T
FAU - Janmey, Paul A
AU  - Janmey PA
FAU - Uibo, Raivo
AU  - Uibo R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Autoantibodies)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Neurofilament Proteins)
RN  - 0 (neurofilament protein L)
RN  - 108688-71-7 (neurofilament protein H)
RN  - 111365-29-8 (neurofilament protein M)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Autoantibodies/*blood
MH  - Child
MH  - Child, Preschool
MH  - Down Syndrome/*diagnosis/genetics/immunology
MH  - Gene Frequency
MH  - HLA-DR Antigens/genetics
MH  - Humans
MH  - Immunoblotting
MH  - Infant
MH  - Middle Aged
MH  - Neurofilament Proteins/*immunology/metabolism
MH  - Phosphorylation
MH  - Prognosis
MH  - Young Adult
EDAT- 2009/09/18 06:00
MHDA- 2009/10/30 06:00
CRDT- 2009/09/18 06:00
PHST- 2009/09/18 06:00 [entrez]
PHST- 2009/09/18 06:00 [pubmed]
PHST- 2009/10/30 06:00 [medline]
AID - NYAS4624 [pii]
AID - 10.1111/j.1749-6632.2009.04624.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2009 Sep;1173:130-6. doi: 10.1111/j.1749-6632.2009.04624.x.